Marinomed Biotech AG Enters Negotiations for Carragelose Portfolio Sale

On October 11, 2024, Marinomed Biotech AG announced its decision to enter preliminary contract negotiations for selling its Carragelose portfolio. This decision follows a thorough evaluation of existing offers. The company aims to arrange an asset deal, selecting a potential buyer who meets their criteria for price, transaction security, and strategic alignment to ensure long-term prospects.

The completion of this transaction is contingent on several approvals, including those from the Supervisory Board, the General Shareholder Assembly, and the insolvency court. These approvals are critical as Marinomed Biotech AG is undergoing a restructuring process. The company has not yet secured the necessary permissions from the insolvency administrator and court.